Fig. 10

XMU-MP-1 improves cognitive and mitochondrial function in 8-month-old 5xFAD mice. A Schematic of experimental proposition in vivo after treatment XMU-MP-1. B–E MWM test results of four groups (C57 + DMSO, C57 + XMU-MP-1, 5xFAD + DMSO, 5xFAD + XMU-MP-1) of mice, including swimming speed (B), escape latency (C), total time spent in the target quadrant (D), Number of platform crossings (E). (n = 10/group). F, G Relative levels of MST1, p-MST1 protein in the hippocampus (n = 4). H, I Relative levels of PSD95, and SYP protein in the hippocampus (n = 4). J, K Relative levels of Bax, Bcl-2, Cleaved Caspase 3, Cleaved Caspase 9 protein in the hippocampus (n = 4). L, M Relative levels of Mitochondrial biogenic protein (PGC1α, Nrf1) in the hippocampus (n = 4). N, O Relative levels of MT-ND4L, MT-ATP6, and MT-CO2 in the hippocampus (n = 4). P, Q Relative levels of PI3K, Akt, and p-Akt protein in the hippocampus (n = 4). All data represent means ± SEMs. *, Comparison between C57 + DMSO and 5xFAD + DMSO group, *p < 0.05; **p < 0.01 and ***p < 0.001. #, Comparison between 5xFAD + DMSO and 5xFAD + XMU-MP-1 group, #p < 0.05; ###p < 0.001